Fig 2: Association of CDCA5 mRNA expression with the immune score and stromal score from TCGA database. mRNA expression level of CDCA5 was presented as FPKM.

Fig 3: Associations between CDCA5 mRNA expression and TMB and MSI in cancers from TCGA database. (A), Radar map of association between CDCA5 expression and TMB; (B), Radar map of association between CDCA5 expression and MSI. *p<0.05; **p<0.01; ***p<0.001.

Fig 4: Expression levels of CDCA5 in pan-cancer. (A), Boxplot of the mRNA expression of CDCA5 in 31 solid cancer types from TCGA database. mRNA expression level of CDCA5 was presented as FPKM. Wilcoxon test was used for statistical analysis. (B), CDCA5 protein intensity in different human normal tissues from the HPA database. (C), The ratio of CDCA5 protein detection in different cancer types from the HPA database. (D), Expression levels of CDCA5 mRNA in LUAD group were higher than those in normal group. Y‑axis data was presented as relative expression normalized to GAPDH; calculated using the 2−ΔΔCt method. (E), Representative IHC staining of CDCA5 in LUAD tissues. *p< 0.05; **p< 0.01; ***p< 0.001.

Fig 5: Kaplan-Meier survival curves comparing the expression of CDCA5 in pan-cancer from TCGA database. (A), Kaplan–Meier OS curves for CDCA5 in 9 cancer types; (B), Kaplan–Meier DSS curves for CDCA5 in 13 cancer types; (C), Kaplan–Meier DFI curves for CDCA5 in 8 cancer types; (D), Kaplan–Meier PFI curves for CDCA5 in 12 cancer types.